Artificial Intelligence in the Life Sciences

Artificial Intelligence in the Life Sciences is a gold open access journal that Elsevier launched in 2021 to publish practical applications and theoretical advances of artificial intelligence across the life sciences, and it recorded a 2025 Journal Impact Factor of 5.1.《生命科学中的人工智能》（Artificial Intelligence in the Life Sciences）是（Elsevier）于 2021 年创办的金色开放获取期刊，刊载人工智能在生命科学领域的实际应用与理论进展，2025 年期刊影响因子为 5.1。

Scope

• The journal covers general, molecular and systems biology, where machine learning and deep learning are brought to bear on biological data at scale.覆盖普通生物学、分子生物学与系统生物学，即机器学习与深度学习在大规模生物数据上的应用。
• Population and disease genetics, including genomic prediction, variant interpretation and the analysis of large patient cohorts.群体遗传学与疾病遗传学，包括基因组预测、变异解读与大规模患者队列分析。
• Medicinal chemistry and chemical biology, from molecular representation and generative design to bioactivity and property modelling.药物化学与化学生物学，从分子表征、生成式设计到生物活性与性质建模。
• Pharmacology and drug discovery, including virtual screening, absorption and toxicity prediction, and drug repurposing.药理学与药物发现，包括虚拟筛选、吸收与毒性预测以及药物重定位。
• Epidemiology and clinical investigations, such as risk modelling, diagnostic decision support and real-world evidence.流行病学与临床研究，如风险建模、诊断决策支持与真实世界证据。
• Methodological work is equally in scope, and the stated keywords are artificial intelligence, machine learning, machine intelligence, deep learning, data mining and big data.方法学研究同样在范围内，官方关键词为人工智能、机器学习、机器智能、深度学习、数据挖掘与大数据。

History

• Elsevier opened the journal in 2021 as a fully open access title, and its first volume established the continuous article numbering that still identifies papers.（Elsevier）于 2021 年以完全开放获取方式创刊，首卷即确立了沿用至今的连续文章编号。
• The launch editorial by Mingyue Zheng, Carolina Horta Andrade and Jurgen Bajorath set out an interdisciplinary programme that pairs AI methods with experimental life science.（Mingyue Zheng）、（Carolina Horta Andrade）与（Jurgen Bajorath）撰写的创刊社论提出把人工智能方法与实验生命科学结合起来的跨学科纲领。^[1]
• Since 2023 the journal has issued two volumes a year and numbers articles continuously instead of paginating issues, so volumes 3 and 4 both belong to 2023.自 2023 年起每年出版两卷，论文以连续文章编号而非页码编排，因此第 3 卷与第 4 卷同属 2023 年。
• Authors pay an article publishing charge of USD 2,070 and choose between the CC BY, CC BY-NC and CC BY-NC-ND licences.作者需支付 2,070 美元的文章出版费，可在（CC BY）、（CC BY-NC）与（CC BY-NC-ND）三种许可中选择。
• The 2025 Journal Impact Factor is 5.1, after 5.4 in 2024, and the title is indexed in ESCI, Scopus and DOAJ.2025 年期刊影响因子为 5.1，2024 年为 5.4，本刊被（ESCI）、（Scopus）与（DOAJ）收录。
• In 2026 the editor-in-chief restated the aims of the journal and added explicit quality criteria for publications.2026 年主编重申刊物宗旨，并补充了明确的发表质量标准。^[2]

Editors

• Jurgen Bajorath of the University of Bonn in Germany is editor-in-chief, with interests in structure-activity relationships, machine learning, virtual screening and compound activity data mining.德国波恩大学的（Jurgen Bajorath）担任主编，研究兴趣包括构效关系、机器学习、虚拟筛选与化合物活性数据挖掘。
• Raquel Rodriguez-Perez of the Novartis Institutes for BioMedical Research in Basel is an associate editor for machine learning, cheminformatics and drug discovery.（Novartis）巴塞尔生物医学研究所的（Raquel Rodriguez-Perez）为副编辑，负责机器学习、化学信息学与药物发现。
• Mingyue Zheng of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, is the other associate editor, covering drug design, artificial intelligence and medicinal chemistry.中国科学院上海药物研究所的（Mingyue Zheng）为另一位副编辑，负责药物设计、人工智能与药物化学。
• In 2024 the board listed 36 editors and board members from 13 countries and regions, led by the United Kingdom and the United States with seven each and China with four.2024 年编委会列出 36 位编辑与编委，来自 13 个国家和地区，其中英国与美国各 7 位、中国 4 位。
• Peer review is single anonymous, and the journal encourages combined computational and experimental studies while accepting pure applications of existing methods only when the findings are of special significance.同行评审采用单盲方式，刊物鼓励计算与实验相结合的研究，仅当结果具有特殊意义时才接受对既有方法的单纯应用。